CD99L2

Summary

CD99L2 (CD99 molecule like 2, HGNC:18237) is a protein-coding gene on chromosome Xq28, encoding CD99 antigen-like protein 2 (Q8TCZ2). Plays a role in a late step of leukocyte extravasation helping cells to overcome the endothelial basement membrane.

This gene encodes a cell-surface protein that is similar to CD99. A similar protein in mouse functions as an adhesion molecule during leukocyte extravasation. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 83692 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 134 total — 2 pathogenic
• MANE Select transcript: NM_031462

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18237
Approved symbol	CD99L2
Name	CD99 molecule like 2
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	CD99B
Ensembl gene	ENSG00000102181
Ensembl biotype	protein_coding
OMIM	300846
Entrez	83692

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 21 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000346693, ENST00000355149, ENST00000370377, ENST00000418547, ENST00000437787, ENST00000466436, ENST00000491877, ENST00000634795, ENST00000881084, ENST00000881086, ENST00000881089, ENST00000881090, ENST00000881091, ENST00000881092, ENST00000954707, ENST00000954708, ENST00000954709, ENST00000954710, ENST00000954711, ENST00000954712, ENST00000954713, ENST00000954714, ENST00000954715

RefSeq mRNA: 5 — MANE Select: NM_031462 NM_001184808, NM_001242614, NM_031462, NM_134445, NM_134446

CCDS: CCDS14697, CCDS14698, CCDS35427, CCDS55527

Canonical transcript exons

ENST00000370377 — 11 exons

Exon	Start	End
ENSE00001261819	150898522	150898668
ENSE00001754630	150777444	150777482
ENSE00003466725	150795418	150795486
ENSE00003533345	150814862	150814936
ENSE00003547583	150793691	150793756
ENSE00003572850	150776174	150776293
ENSE00003594849	150816007	150816078
ENSE00003597636	150795206	150795289
ENSE00003608834	150770304	150770369
ENSE00003681174	150766336	150769101
ENSE00003682869	150831231	150831293

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 97.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.2702 / max 387.5476, expressed in 1817 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200830	41.9551	1816
200831	2.0763	975
200833	0.5940	259
200832	0.3196	137
200828	0.2094	65
200834	0.1159	49

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prefrontal cortex	UBERON:0000451	97.53	gold quality
gastrocnemius	UBERON:0001388	97.45	gold quality
right frontal lobe	UBERON:0002810	97.15	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.11	gold quality
muscle of leg	UBERON:0001383	97.08	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.01	gold quality
frontal cortex	UBERON:0001870	96.58	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.57	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.37	gold quality
hypothalamus	UBERON:0001898	96.24	gold quality
anterior cingulate cortex	UBERON:0009835	96.22	gold quality
spinal cord	UBERON:0002240	96.09	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.09	gold quality
neocortex	UBERON:0001950	96.04	gold quality
pons	UBERON:0000988	95.99	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.81	gold quality
left ventricle myocardium	UBERON:0006566	95.72	gold quality
tibialis anterior	UBERON:0001385	95.63	gold quality
tibial nerve	UBERON:0001323	95.52	gold quality
cerebellar cortex	UBERON:0002129	95.30	gold quality
cerebellar hemisphere	UBERON:0002245	95.29	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.27	gold quality
putamen	UBERON:0001874	95.18	gold quality
apex of heart	UBERON:0002098	95.16	gold quality
cerebral cortex	UBERON:0000956	95.13	gold quality
substantia nigra	UBERON:0002038	95.13	gold quality
stromal cell of endometrium	CL:0002255	95.12	gold quality
nucleus accumbens	UBERON:0001882	95.12	gold quality
postcentral gyrus	UBERON:0002581	95.10	gold quality
cerebellum	UBERON:0002037	94.93	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	28.39
E-ENAD-27	yes	7.81
E-GEOD-81608	no	344.90
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

49 targeting CD99L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-548M	99.70	68.87	1749
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-593-5P	99.34	69.50	965
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-7851-3P	98.72	64.88	980
HSA-MIR-1227-5P	98.65	65.32	1549

Literature-anchored findings (GeneRIF, showing 2)

• This study identified predicted pathogenic, hemizygous variants on chromosome X in disease genes CD99L2. (PMID:25666757)
• Human CD99L2 Regulates a Unique Step in Leukocyte Transmigration. (PMID:35914838)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd99l2	ENSDARG00000056722
mus_musculus	Cd99l2	ENSMUSG00000035776
rattus_norvegicus		ENSRNOG00000088438
rattus_norvegicus	Cd99l2	ENSRNOG00000089435

Paralogs (1): CD99 (ENSG00000002586)

Protein

Protein identifiers

CD99 antigen-like protein 2 — Q8TCZ2 (reviewed: Q8TCZ2)

Alternative names: MIC2-like protein 1

All UniProt accessions (5): Q8TCZ2, A0A024RC16, A0A0S2Z5R8, A0A0U1RQT8, H0Y4H3

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in a late step of leukocyte extravasation helping cells to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1. Homophilic adhesion molecule, but these interactions may not be required for cell aggregation.

Subcellular location. Cell membrane. Cell junction. Secreted.

Tissue specificity. Detected in cerebrospinal fluid (at protein level). Expressed in many tissues, with low expression in thymus.

Post-translational modifications. O-glycosylated.

Similarity. Belongs to the CD99 family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q8TCZ2-1	1	yes
Q8TCZ2-2	2
Q8TCZ2-3	3
Q8TCZ2-4	4
Q8TCZ2-5	5
Q8TCZ2-6	6

RefSeq proteins (5): NP_001171737, NP_001229543, NP_113650, NP_604394, NP_604395 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR022078	CD99L2	Family

Pfam: PF12301

UniProt features (24 total): splice variant 8, sequence conflict 5, compositionally biased region 4, topological domain 2, signal peptide 1, chain 1, glycosylation site 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TCZ2-F1	55.71	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 178

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-109582	Hemostasis

MSigDB gene sets: 155 (showing top): GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_POSITIVE_REGULATION_OF_LYMPHOCYTE_MIGRATION, GOBP_POSITIVE_REGULATION_OF_CELLULAR_EXTRAVASATION, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOCC_CELL_SURFACE, CAGCTG_AP4_Q5, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_MONONUCLEAR_CELL_MIGRATION, GOBP_CELLULAR_EXTRAVASATION, GOBP_LEUKOCYTE_MIGRATION, GOBP_POSITIVE_REGULATION_OF_NEUTROPHIL_MIGRATION, GOBP_POSITIVE_REGULATION_OF_LEUKOCYTE_MIGRATION, HEN1_01, GOBP_GRANULOCYTE_MIGRATION, GOBP_REGULATION_OF_CELLULAR_EXTRAVASATION

GO Biological Process (4): cell adhesion (GO:0007155), diapedesis (GO:0050904), positive regulation of neutrophil extravasation (GO:2000391), positive regulation of T cell extravasation (GO:2000409)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), plasma membrane (GO:0005886), adherens junction (GO:0005912), focal adhesion (GO:0005925), cell surface (GO:0009986), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Hemostasis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
positive regulation of cellular extravasation	2
cellular process	1
cellular extravasation	1
leukocyte migration	1
neutrophil extravasation	1
positive regulation of neutrophil migration	1
regulation of neutrophil extravasation	1
T cell extravasation	1
positive regulation of T cell migration	1
regulation of T cell extravasation	1
binding	1
membrane	1
cell periphery	1
cell-cell junction	1
cell-substrate junction	1
cell junction	1

Protein interactions and networks

STRING

1124 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD99L2	PILRA	Q9UKJ1	968
CD99L2	PILRB	Q9UKJ0	936
CD99L2	CD99	P14209	849
CD99L2	CD34	P28906	840
CD99L2	EWSR1	Q01844	825
CD99L2	SYP	P08247	791
CD99L2	PECAM1	P16284	775
CD99L2	ENO2	P09104	773
CD99L2	PTPRC	P08575	726
CD99L2	KIT	P10721	720
CD99L2	BCL2	P10415	720
CD99L2	MME	P08473	720
CD99L2	NCAM1	P13591	720
CD99L2	SPN	P16150	719
CD99L2	MYOG	P15173	713
CD99L2	CALB2	P22676	713

IntAct

65 interactions, top by confidence:

A	B	Type	Score
CAPN1	CAPNS1	psi-mi:“MI:0914”(association)	0.840
CD99L2	UBQLN1	psi-mi:“MI:0915”(physical association)	0.720
UBQLN1	CD99L2	psi-mi:“MI:0915”(physical association)	0.720
CD99L2	SGTA	psi-mi:“MI:0915”(physical association)	0.720
SGTA	CD99L2	psi-mi:“MI:0915”(physical association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TMBIM6	CD99L2	psi-mi:“MI:0915”(physical association)	0.560
TRAM1L1	CD99L2	psi-mi:“MI:0915”(physical association)	0.560
SLC30A8	CD99L2	psi-mi:“MI:0915”(physical association)	0.560
CD99L2	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
CD99L2	SGTB	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (52): CD99L2 (Two-hybrid), CD99L2 (Proximity Label-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS), CD99L2 (Affinity Capture-MS)

ESM2 similar proteins: A1A4K1, B1H3G4, E9PV24, O35988, O61704, O75167, O93383, P14209, P14599, P15514, P24338, P31431, P31955, P34741, P34900, P34901, P43322, P43407, P49414, P49416, P50605, P55808, P58239, Q02297, Q0VFF9, Q1RMT9, Q27913, Q56A20, Q58DD4, Q5RAT9, Q5RCS3, Q5RE35, Q5REP3, Q5XG99, Q6DBW9, Q6GR51, Q6PKG0, Q6ZQ58, Q7SXB3, Q7TMJ8

Diamond homologs: A1A4K1, B1H3G4, P14209, Q5RE35, Q6DBW9, Q8BIF0, Q8R1R5, Q8TCZ2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 36 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
regulation of macroautophagy	5	43.5×	3e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	51
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2685725	GRCh37/hg19 Xq28(chrX:149650839-149937387)x1	Pathogenic
4076026	GRCh37/hg19 Xq28(chrX:149348005-150139922)x0	Pathogenic

SpliceAI

2417 predictions. Top by Δscore:

Variant	Effect	Δscore
X:150770365:ACCCT:A	acceptor_gain	1.0000
X:150770366:CCCT:C	acceptor_gain	1.0000
X:150770366:CCCTC:C	acceptor_gain	1.0000
X:150770367:CCTC:C	acceptor_gain	1.0000
X:150770368:CT:C	acceptor_gain	1.0000
X:150770368:CTCTG:C	acceptor_loss	1.0000
X:150770370:C:CC	acceptor_gain	1.0000
X:150770371:T:A	acceptor_loss	1.0000
X:150776166:GCACT:G	donor_loss	1.0000
X:150776169:CTTAC:C	donor_loss	1.0000
X:150776170:T:TC	donor_loss	1.0000
X:150776171:T:TG	donor_loss	1.0000
X:150776172:A:AC	donor_gain	1.0000
X:150776172:A:AT	donor_loss	1.0000
X:150776172:ACG:A	donor_gain	1.0000
X:150776173:C:CG	donor_gain	1.0000
X:150776173:CG:C	donor_gain	1.0000
X:150776173:CGC:C	donor_gain	1.0000
X:150776173:CGCTG:C	donor_gain	1.0000
X:150776289:CATGC:C	acceptor_gain	1.0000
X:150776290:ATGC:A	acceptor_gain	1.0000
X:150776291:TGC:T	acceptor_gain	1.0000
X:150776292:GC:G	acceptor_gain	1.0000
X:150776293:CC:C	acceptor_gain	1.0000
X:150776293:CCTG:C	acceptor_loss	1.0000
X:150776294:C:CA	acceptor_loss	1.0000
X:150776294:C:CC	acceptor_gain	1.0000
X:150776298:G:C	acceptor_gain	1.0000
X:150776298:G:GC	acceptor_gain	1.0000
X:150795201:CTCA:C	donor_loss	1.0000

AlphaMissense

1698 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:150776253:G:C	S192R	0.998
X:150776253:G:T	S192R	0.998
X:150776255:T:G	S192R	0.998
X:150776217:G:C	S204R	0.997
X:150776217:G:T	S204R	0.997
X:150776219:T:G	S204R	0.997
X:150776230:C:T	G200D	0.995
X:150776227:G:T	A201D	0.994
X:150776239:G:T	A197D	0.994
X:150776242:A:T	M196K	0.994
X:150776184:G:C	F215L	0.993
X:150776184:G:T	F215L	0.993
X:150776186:A:G	F215L	0.993
X:150776242:A:C	M196R	0.993
X:150776245:G:T	A195D	0.993
X:150776251:G:T	A193D	0.992
X:150776224:A:T	V202D	0.991
X:150776216:A:C	Y205D	0.989
X:150776236:A:T	L198H	0.989
X:150776228:C:G	A201P	0.988
X:150776231:C:G	G200R	0.986
X:150776257:G:T	A191D	0.986
X:150776188:C:T	C214Y	0.985
X:150776266:G:T	A188D	0.983
X:150776236:A:G	L198P	0.982
X:150776189:A:G	C214R	0.980
X:150776233:A:T	I199N	0.979
X:150776236:A:C	L198R	0.979
X:150776188:C:G	C214S	0.978
X:150776189:A:T	C214S	0.978

dbSNP variants (sampled 300 via entrez): RS1000004106 (X:150878712 T>C,G), RS1000022512 (X:150781463 G>A), RS1000182860 (X:150832459 A>G), RS1000296065 (X:150845741 A>C), RS1000300751 (X:150770767 T>C), RS1000412242 (X:150895534 G>A), RS1000417005 (X:150818793 G>A), RS1000597803 (X:150843239 A>G), RS1000630431 (X:150843577 G>A), RS1000701679 (X:150785105 C>G,T), RS1000736911 (X:150893399 T>C), RS1000745109 (X:150893732 T>C), RS1000783323 (X:150834170 A>C), RS1000790321 (X:150776346 C>G,T), RS1000849360 (X:150836211 G>A)

Disease associations

OMIM: gene MIM:300846 | disease phenotypes: MIM:310400, MIM:310440, MIM:147421

GenCC curated gene-disease

Mondo (4): X-linked myotubular myopathy (MONDO:0010683), X-linked myopathy with excessive autophagy (MONDO:0010684), inclusion body myositis (MONDO:0007827), neurodevelopmental disorder (MONDO:0700092)

Orphanet (3): X-linked myopathy with excessive autophagy (Orphanet:25980), X-linked centronuclear myopathy (Orphanet:596), Inclusion body myositis (Orphanet:611)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D018979	Myositis, Inclusion Body	C05.651.594.600; C10.668.491.562.500
D065886	Neurodevelopmental Disorders	F03.625
C536522	Vacuolar myopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression, affects cotreatment, increases abundance, increases expression	4
Valproic Acid	affects cotreatment, decreases expression, increases methylation	4
entinostat	decreases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases expression, increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Atrazine	increases expression	1
Carbamazepine	affects expression	1
Catechin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

284 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02573467	PHASE3	COMPLETED	An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
NCT04049097	PHASE3	TERMINATED	Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
NCT04789070	PHASE3	ACTIVE_NOT_RECRUITING	Phase III Trial of Sirolimus in IBM
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT00001261	PHASE2	COMPLETED	Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
NCT01423110	PHASE2	COMPLETED	Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT02753530	PHASE2	COMPLETED	Study of Arimoclomol in Inclusion Body Myositis (IBM)
NCT03710941	PHASE2	WITHDRAWN	Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
NCT04062019	PHASE2	UNKNOWN	Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
NCT04237987	PHASE2	UNKNOWN	Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
NCT04687111	PHASE2	UNKNOWN	Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
NCT06794008	PHASE2	RECRUITING	BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT01519349	PHASE1	COMPLETED	Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
NCT02483845	PHASE1	UNKNOWN	Natalizumab in Inclusion Body Myositis (IBM)
NCT03440034	PHASE1	COMPLETED	Study of Pioglitazone in Sporadic Inclusion Body Myositis
NCT04421677	PHASE1	COMPLETED	Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
NCT04659031	PHASE1	COMPLETED	A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
NCT05032131	PHASE1	UNKNOWN	Cell Therapy for IBM by Muscle Injection of ADSVF
NCT06524687	PHASE1	TERMINATED	A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
NCT06941129	PHASE1	RECRUITING	CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06978647	PHASE1	RECRUITING	A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978738	PHASE1	NOT_YET_RECRUITING	UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07104721	PHASE1	RECRUITING	A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07123519	PHASE1	RECRUITING	A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07236762	PHASE1	RECRUITING	An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236801	PHASE1	RECRUITING	Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
NCT07413341	PHASE1	RECRUITING	A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03199469	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)